Pharmacotherapy for Alzheimer's disease: progress and prospects
- PMID: 12237155
- DOI: 10.1016/s0165-6147(02)02056-4
Pharmacotherapy for Alzheimer's disease: progress and prospects
Abstract
The number of people with Alzheimer's disease has never been greater and is set to increase substantially in the decades ahead as the proportion of the population aged 65 years or more rises sharply. There is, therefore, a substantial and increasing need for effective pharmacotherapy. Increased understanding of disease pathophysiology has led to palliative treatments for both cognitive and non-cognitive changes in behaviour. This, together with the prospect of drugs that slow or perhaps even halt the course of the disease, raises hope that this devastating disorder will soon be more amenable to pharmacotherapy with new drugs that either ameliorate specific symptoms or alter the course of the disease.
Similar articles
-
Neuroprotective therapeutics for Alzheimer's disease: progress and prospects.Trends Pharmacol Sci. 2011 Mar;32(3):141-7. doi: 10.1016/j.tips.2010.12.007. Epub 2011 Jan 20. Trends Pharmacol Sci. 2011. PMID: 21256602 Review.
-
Neurochemical basis for symptomatic treatment of Alzheimer's disease.Neuropharmacology. 2010 Sep-Oct;59(4-5):221-9. doi: 10.1016/j.neuropharm.2010.02.010. Epub 2010 Feb 13. Neuropharmacology. 2010. PMID: 20156462 Review.
-
Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study.Ann Neurol. 2002 May;51(5):567-77. doi: 10.1002/ana.10161. Ann Neurol. 2002. PMID: 12112102
-
Neuropathologic changes in Alzheimer's disease.J Clin Psychiatry. 2003;64 Suppl 9:7-10. J Clin Psychiatry. 2003. PMID: 12934968 Review.
-
Pharmaceutical treatment of cognitive disorders in Alzheimer's disease.Funct Neurol. 1997 May-Aug;12(3-4):211-2. Funct Neurol. 1997. PMID: 9218980 No abstract available.
Cited by
-
Escitalopram Ameliorates Forskolin-Induced Tau Hyperphosphorylation in HEK239/tau441 Cells.J Mol Neurosci. 2015 Jun;56(2):500-8. doi: 10.1007/s12031-015-0519-4. Epub 2015 Feb 17. J Mol Neurosci. 2015. PMID: 25687330
-
Rodent Models of Amyloid-Beta Feature of Alzheimer's Disease: Development and Potential Treatment Implications.Aging Dis. 2020 Oct 1;11(5):1235-1259. doi: 10.14336/AD.2019.1026. eCollection 2020 Oct. Aging Dis. 2020. PMID: 33014535 Free PMC article. Review.
-
Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice.Br J Pharmacol. 2009 Aug;157(7):1270-7. doi: 10.1111/j.1476-5381.2009.00295.x. Epub 2009 Jun 22. Br J Pharmacol. 2009. PMID: 19552690 Free PMC article.
-
The Use of Pluripotent Stem Cell-Derived Organoids to Study Extracellular Matrix Development during Neural Degeneration.Cells. 2019 Mar 14;8(3):242. doi: 10.3390/cells8030242. Cells. 2019. PMID: 30875781 Free PMC article. Review.
-
Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.Neurotherapeutics. 2008 Jul;5(3):433-42. doi: 10.1016/j.nurt.2008.05.002. Neurotherapeutics. 2008. PMID: 18625455 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical